Anti-Human Siglec-2/CD22 Recombinant Antibody (RFB-4) (HB011307)

Name: Anti-Human Siglec-2/CD22 Recombinant Antibody (RFB-4)
Brand: abinScience
SKU: HB011307
Price: 191 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

50ug
100ug

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HB011307
種反応性	Human
アプリケーション	ELISA, FCM
宿主種	Mouse
クローン性	Monoclonal
アイソタイプ	IgG1, kappa
クローンID	RFB-4
テスト済みアプリケーション	FCM
ターゲット	B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P20273
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
背景	B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366
参考文献	1. Kreitman RJ, et al. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer. 1999 Mar 31;81(1):148-55. [HB011307] 2. Mansfield E, et al. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90(5):2020-2026. [HB011307]
注意事項	For research use only.

イメージ

Bioactivity

Detects CD22 in indirect ELISAs.
Flow Cytometry

Flow-cytometry using anti-human CD22 antibody.Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD22 antibody monoclonal antibody (Catalog # HB011307 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-mouse antibody (Catalog # MF690414) and cells analysed on a NovoCyte Flow Cytometer.